JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

The Evolution and Therapeutic Benefits of Follow-on Pharmaceuticals

Syed Ansar Ahmed*[1], Bherje Varsha Digamber[2], Nilkanth Madhavrao Alewad[3], Nawab Shadulsab Pinjari[4]

[1] *Associate Professor, Department of Pharmaceutical Chemistry, Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra, India*
[2] *Associate Professor, Department of Pharmacology, Ramesh Patil institute of Pharmacy, Nanded, Maharashtra, India*
[3] *Assistant Professor, Department of Pharmacology, Shrimati Latatai Baburao Patil Institute of Pharmacy, Bendri, Nanded, Maharashtra, India*
[4] *Assistant Professor, Department of Quality Assurance, Ramesh Patil Institute of Pharmacy, Nanded, Maharashtra, India*

Publication history: Received on 20th November 2025; Revised on 30th December 2025; Accepted on 5th January 2026

Article DOI: 10.69613/hbhm6305

Abstract: The pharmaceutical era is increasingly defined by the emergence of follow-on drugs, often referred to as "me-too" medications. These agents include subsequent entries within an existing therapeutic class, sharing a similar mechanism of action with a first-in-class prototype. While often criticized as redundant, the iterative development of structural analogs provides essential clinical advantages, including optimized pharmacokinetics, reduced side-effect profiles, and enhanced patient adherence. From a market perspective, the presence of multiple competitors within a single drug class facilitates price competition and ensures supply chain resilience. This analysis details the scientific nuances of structural modifications, the regulatory guidelines governing their approval, and the economic factors that incentivize incremental innovation over radical discovery. Case studies in HMG-CoA reductase inhibitors, proton pump inhibitors, and selective serotonin reuptake inhibitors show that follow-on agents frequently surpass the efficacy or safety of their precursors. The connection between incremental chemical refinement and therapeutic diversification suggests that follow-on drugs are not merely imitative but are central to the maturation of modern pharmacotherapy.

Keywords: Follow-on drugs; Pharmacokinetics; Incremental innovation; Therapeutic competition; Pharmaceutical economics

1. Introduction

The discovery of novel chemical entities frequently yields a prototype drug that establishes a new therapeutic category. However, the commercial and clinical success of such prototypes almost invariably triggers the development of follow-on drugs. These subsequent agents are designed to target the same biological pathways but possess distinct molecular structures that may alter their interaction with receptors or metabolic enzymes [1]. In modern medicine, a significant portion of the pharmaceutical market consists of these follow-on products, which often emerge shortly after or even before the patent expiration of the primary innovator [2]. This sequence of events is not merely a commercial byproduct but a reflection of the iterative nature of biomedical progress.

Historically, the emergence of follow-on agents has been viewed through a skeptical lens by some within the scientific and policy communities. Critics often argue that the proliferation of "me-too" drugs a term frequently used disparagingly misallocates research and development resources away from addressing unmet medical needs and toward the pursuit of redundant commercial gains. This perspective posits that the existence of multiple drugs with similar mechanisms of action provides little added value to the therapeutic landscape. However, a more granular scientific analysis suggests that the first drug in a class is rarely the most optimized version [3]. The initial molecule, while revolutionary for its role in validating a biological target, often carries significant pharmacological liabilities. These may include poor oral bioavailability, a short half-life necessitating frequent dosing, or a lack of receptor subtype selectivity that results in off-target effects, thereby limiting its clinical utility and patient tolerance.

Follow-on development is a vital phase of pharmaceutical maturation. It allows for the systematic refinement of molecular parameters through sophisticated medicinal chemistry, leading to superior clinical outcomes [4]. Researchers can enhance the "drug-likeness" of a compound, by modifying the chemical scaffold of a pioneer molecule potentially reducing toxicities or improving the predictability of the therapeutic response. This process is not a simple imitation; it is a rigorous exercise in optimization that transforms a proof-of-concept into a reliable clinical tool. For instance, the transition from early, non-selective beta-blockers to cardioselective agents indicated how follow-on innovation can drastically improve the safety profile for specific patient populations.

* Corresponding author: Syed Ansar Ahmed

The presence of multiple agents within a single class is essential for personalizing medicine. Due to the high degree of inter-individual variability in drug metabolism and response, a patient who experiences adverse effects or a lack of efficacy with a pioneer agent may find a follow-on drug to be highly effective. This therapeutic diversity ensures that a larger percentage of the patient population can achieve the desired clinical goals without compromising on safety. Genetic polymorphisms in metabolic enzymes, such as the cytochrome P450 system, mean that no single drug is universally optimal for every individual. Having a suite of follow-on options allows clinicians to tailor therapy to the unique physiological profile of the patient.

From an economic and public health standpoint, the role of follow-on drugs is equally significant. The market entry of subsequent agents introduces competition into a therapeutic class, which can drive down the cost of treatments even while the pioneer remains under patent protection. This competition pressures manufacturers to show that their follow-on agent offers some distinct clinical or practical advantage over the incumbent to gain market share. Moreover, the existence of multiple manufacturers for essential drug classes enhances supply chain resilience, preventing shortages that could occur if a single production facility for a pioneer drug were to face disruptions. This review provides the scientific justification for follow-on drugs, the mechanisms of their development, and their role in the broader healthcare ecosystem.

2. Follow-on Pharmaceuticals

To understand the scientific relevance of these agents, it is necessary to distinguish between simple imitation and incremental refinement. A follow-on drug is defined as a therapeutic agent that belongs to a class where a pioneer drug has already been approved, targeting the same mechanism but featuring a unique chemical structure [5].

2.1. Structural Variation within Functional Classes

The term "me-too" is often a misnomer in medicinal chemistry because it implies identity. In reality, follow-on drugs are distinct chemical entities. Even minor modifications, such as the addition of a fluorine atom or the change of a side chain, can drastically alter the lipophilicity and binding affinity of a molecule [6].

2.1.1. Isomeric Refinement

One common strategy in follow-on development involves the transition from a racemic mixture to a single enantiomer. For example, the development of esomeprazole as a follow-on to omeprazole focused on the S-enantiomer, which exhibited slower metabolism and more predictable plasma concentrations [7]. This shift represents a technical advancement that improves the predictability of the therapeutic response.

Table 1. Stereoisomeric Refinements

Racemic Pioneer	Single-Enantiomer Follow-on	Justification
Omeprazole (R/S)	Esomeprazole (S)	Reduced inter-individual metabolic variation; higher area under the curve (AUC).
Citalopram (R/S)	Escitalopram (S)	Removal of the R-enantiomer which may antagonize the S-enantiomer's binding.
Albuterol (R/S)	Levalbuterol (R)	Avoidance of the S-enantiomer, which may contribute to pro-inflammatory effects.
Cetirizine (R/S)	Levocetirizine (R)	Higher affinity for H1-receptors; lower dosage required for therapeutic effect.

2.1.2. Bioisosteric Replacement

Bioisosterism is frequently employed to create follow-on agents that maintain the pharmacophore of the pioneer while improving stability. Researchers can prolong the duration of action or reduce the formation of toxic metabolites by replacing a specific functional group with a bioisostere, thereby creating a safer alternative to the first-in-class agent [8].

The history of pharmacology is replete with examples where the second or third drug in a class became the "gold standard." The development of sulfonamides in the mid-20th century established the precedent for iterative chemical modification to expand the spectrum of activity and reduce renal toxicity [9].

Table 2. Examples of Pioneer vs. Follow-on Drugs in Major Therapeutic Classes

Therapeutic Class	Pioneer Drug (First-in-Class)	Notable Follow-on Drugs	Structural/Functional Evolution
Statins (HMG-CoA Reductase)	Lovastatin	Atorvastatin, Rosuvastatin	Transition from fungal-derived to fully synthetic; increased binding affinity.
Proton Pump Inhibitors	Omeprazole	Esomeprazole, Rabeprazole	Isomeric refinement (S-enantiomer) and altered activation kinetics.
SSRIs	Fluoxetine	Sertraline, Escitalopram	Divergent chemical scaffolds to reduce CYP450 drug-drug interactions.
ACE Inhibitors	Captopril	Enalapril, Lisinopril	Elimination of sulfhydryl group to reduce skin rash/taste disturbances.
H2-Receptor Antagonists	Cimetidine	Ranitidine, Famotidine	Improved potency and reduced anti-androgenic side effects.

2.2. Historical Context and Evolution

2.2.1. The Era of Serendipity vs. Rational Design

Early follow-on drugs were often the result of competing laboratories discovering similar compounds simultaneously. In the modern era, the process is highly deliberate. Computer-aided drug design allows scientists to map the binding pockets of receptors with high precision, enabling the creation of follow-on molecules that fit more tightly or more selectively than the original prototype [10].

2.2.2. Regulatory Milestones

The regulatory environment has also shaped the trajectory of follow-on drugs. Historically, proving "substantial evidence of effectiveness" was sufficient for approval. More recently, regulatory bodies have begun to look for evidence of incremental benefit, although the primary requirement remains safety and efficacy relative to a placebo or a standard of care [11]. This has encouraged manufacturers to focus on "niche" follow-on drugs that serve specific sub-populations of patients who do not respond well to the pioneer agent



Figure 1. Procedural flow of drug development within a therapeutic class

3. Scientific Rationale Behind Iterative Drug Development

The transition from a pioneer molecule to a follow-on agent is driven by the necessity to address the inherent limitations of first-in-class drugs. While the pioneer establishes the proof of concept for a therapeutic target, it frequently possesses suboptimal pharmaceutical properties that can be rectified through structural modification [12].

3.1. Pharmacokinetic Optimization

Pharmacokinetic (PK) parameters determine the concentration of a drug at its site of action over time. Pioneer drugs often exhibit high variability in absorption or rapid clearance, necessitating frequent dosing intervals that reduce patient compliance [13].

3.1.1. Enhancement of Metabolic Stability

A primary objective in follow-on design is the reduction of first-pass metabolism. Medicinal chemists can extend the half-life of a compound by strategically incorporating halogen atoms or replacing labile esters with more stable amides. In the development of second-generation dihydropyridine calcium channel blockers, the modification of the side chains led to agents like amlodipine, which possesses a significantly longer half-life than nifedipine, allowing for once-daily dosing [14].

3.1.2. Improvement of Bioavailability

Low oral bioavailability is a common hurdle for pioneer compounds. Follow-on agents often utilize prodrug strategies or modifications to lipophilicity to enhance intestinal absorption. The evolution of antiviral nucleoside analogs illustrates this, where valacyclovir (a prodrug) was developed as a follow-on to acyclovir to significantly increase plasma concentrations through active transport mechanisms in the gut [15].

Table 3. Pharmacokinetic Improvements via Follow-on Innovation

Pioneer Drug	Follow-on Agent	PK Improvement	Clinical Benefit
Nifedipine	Amlodipine	Extended half-life (~30-50 hours)	Transition from TID (thrice daily) to once-daily dosing.
Acyclovir	Valacyclovir	Increased oral bioavailability (via L-valine ester)	Higher plasma concentrations; reduced dosing frequency in herpes zoster.
Terfenadine	Fexofenadine	Active metabolite utilized as drug	Elimination of cardiotoxicity risk (QT prolongation) via HERG channel bypass.
L-Dopa	Carbidopa/L-Dopa	Reduced peripheral metabolism	Increased CNS penetration; decreased peripheral nausea/vomiting.

3.2. Pharmacodynamic Refinement and Selectivity

Pharmacodynamics (PD) involves the relationship between drug concentration and the resulting effect. Follow-on drugs are frequently designed to increase potency or selectivity for a specific receptor subtype, thereby minimizing off-target interactions [16].

3.2.1. Subtype Selectivity and Side-Effect Mitigation

Many pioneer drugs interact with multiple receptor isoforms, leading to unwanted physiological responses. The progression of beta-blockers provides a classic example; early non-selective agents like propranolol acted on both β1 and β2 receptors, which could cause bronchoconstriction in asthmatic patients. Follow-on agents like atenolol and metoprolol were engineered for β1 selectivity, offering a safer profile for patients with respiratory comorbidities [17].

Table 4. Receptor Subtype Selectivity in Follow-on Development

Pioneer Approach	Follow-on Approach	Selectivity Shift	Therapeutic Impact
Propranolol	Atenolol	Non-selective β1/β2 → β1 selective	Reduced risk of bronchospasm in patients with asthma/COPD.
Ibuprofen	Celecoxib	Non-selective COX-1/COX-2 → COX-2 selective	Reduced gastrointestinal mucosal injury and ulceration risk.
Diphenhydramine	Loratadine	H1-receptor (crosses BBB) → Peripheral H1 selective	Elimination of sedative effects; improved daytime functionality.
Morphine	Naloxegol	Non-selective Opioid → Peripherally acting μ-opioid	Treatment of opioid-induced constipation without reversing analgesia.

3.2.2. Binding Affinity and Potency

The application of Structure-Activity Relationship (SAR) studies allows for the identification of optimal molecular configurations that maximize binding enthalpy. In the class of HMG-CoA reductase inhibitors (statins), the transition from naturally derived compounds like lovastatin to synthetic follow-on agents like atorvastatin and rosuvastatin resulted in significantly higher binding affinity to the enzyme, allowing for greater LDL cholesterol reduction at lower doses [18].



Figure 2. Methods for optimizing the therapeutic profile of follow-on pharmaceuticals via structural modification.

4. Clinical and Therapeutic Advantages of Diversity

The availability of multiple agents within a single therapeutic class is not redundant but essential for personalizing medicine. Individual patient responses to drugs are highly heterogeneous due to genetic polymorphisms in metabolic enzymes and transporters [19].

4.1. Management of Inter-Individual Variability

Patients who fail to respond to a pioneer drug or who experience intolerable side effects often find relief in a follow-on agent. This phenomenon, known as "switching within the class," is common in psychiatry and cardiology.

4.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs)

While all SSRIs share a common mechanism, they differ significantly in their chemical structures ranging from the phenylpropylamine of fluoxetine to the phenylalkylamine of fluvoxamine. These structural differences lead to varied interactions with cytochrome P450 enzymes. If a patient experiences significant drug-drug interactions or side effects with one SSRI, the availability of follow-on agents like sertraline or escitalopram provides alternative options with different metabolic pathways [20].

4.1.2. Proton Pump Inhibitors (PPIs)

The PPI class shows how follow-on drugs can provide more consistent acid suppression. The development of rabeprazole and pantoprazole followed omeprazole, offering different activation kinetics and less reliance on the CYP2C19 genotype. This ensures that "rapid metabolizers" who might not achieve adequate pH control with the pioneer drug can be successfully treated with a follow-on agent [21].

4.2. Enhancing Patient Adherence

Improvements in dosing frequency and route of administration are direct results of follow-on innovation. A drug that requires three doses a day is significantly more likely to result in non-compliance compared to a follow-on that requires only one. The transition from short-acting to long-acting formulations or more potent analogs is a critical factor in long-term disease management, particularly in chronic conditions like hypertension and diabetes [22].



Figure 3. Clinical decision algorithm for managing inter-individual variability. The "NO" path directs clinicians toward an assessment of therapeutic failure, subsequently leading to an intra-class switch

5. Economic Dynamics and Market Competition

The economic impact of follow-on pharmaceuticals is a subject of significant debate within healthcare policy. While often characterized as a mechanism for extending patent life, the market entry of subsequent agents within a class fundamentally alters the competitive landscape, often to the benefit of payers and patients [23].

5.1. Price Competition and Market Entry

The arrival of a second or third drug in a therapeutic class introduces price competition even before the expiration of the pioneer's patent. In a monopolistic environment, the first-in-class manufacturer has significant leverage over pricing. The entry of follow-on agents forces manufacturers to compete on rebates, formulary placement, and secondary clinical benefits [24].

5.1.1. Therapeutic Interchangeability

From a pharmacoeconomic perspective, follow-on drugs allow for therapeutic interchangeability. Health systems and insurance providers can leverage the existence of multiple similar agents to negotiate lower costs. If three drugs provide equivalent clinical outcomes for the majority of the population, the lowest-priced agent can be designated as the preferred therapy, driving down the overall expenditure for that drug class [25].

Table 5. Economic and Market Impacts of Follow-on Entry

Competitive Dynamic	Description	Resulting Outcome
Price Erosion	Entry of 2nd/3rd class members.	Average class price drops even while pioneer is under patent.
Formulary Leverage	Payers utilize therapeutic equivalence.	Negotiation of higher rebates/discounts for "preferred" status.
Indication Expansion	Follow-ons seek "niche" approvals.	Increased therapeutic options for orphan or secondary conditions.
Generic Acceleration	Diverse class allows for multiple generic entries.	Faster transition to low-cost multi-source environment post-patent.

5.1.2. Supply Chain Resilience

Reliance on a single manufacturer for a critical therapeutic class poses a risk to public health. Follow-on drugs ensure that the supply chain is diversified. In instances of manufacturing failures, recalls, or raw material shortages affecting the pioneer drug, the presence of follow-on agents prevents therapeutic gaps, ensuring that patients maintain access to necessary treatment [26].

5.2. Research and Development Incentives

The development of follow-on drugs is often less risky than the discovery of first-in-class molecules, as the biological target has already been validated. However, the costs associated with Phase III clinical trials and regulatory approval remain substantial [27].

5.2.1. Risk Mitigation in Innovation

The high failure rate of truly novel mechanisms (pioneer drugs) can deter investment. Follow-on development provides a more predictable pathway for pharmaceutical companies to recoup investment, which in turn sustains the financial ecosystem required for more radical, high-risk research. This "incrementalism" provides a steady stream of revenue that supports the broader R&D pipeline [28].

5.2.2. The "Fast Follower" Strategy

Many companies adopt a "fast follower" strategy, aiming to enter the market shortly after a pioneer. This competition accelerates the speed at which therapeutic classes mature. The rapid succession of HMG-CoA reductase inhibitors allowed the medical community to move from the first-generation lovastatin to the highly potent rosuvastatin in a relatively short timeframe, significantly improving the management of cardiovascular risk [29].

6. Regulatory Pathways and Intellectual Property

The approval process for follow-on drugs is governed by the same rigorous standards as pioneer agents, requiring proof of safety and efficacy through randomized controlled trials. However, the legal and intellectual property landscape is distinct.

6.1. Patent and Lifecycle Management

Follow-on drugs are often criticized for "evergreening" the practice of extending patent protection through minor modifications. While companies do seek to protect their investments, each follow-on agent must be granted its own patent based on "non-obviousness" and "utility." This requires the manufacturer to show that the new chemical entity provides a distinct advantage or possesses a unique structure that was not previously described [30].

6.2. Comparative Efficacy Requirements

A significant challenge for follow-on drugs is the increasing demand from regulatory bodies and health technology assessment (HTA) agencies for head-to-head trials. While a drug can be approved based on its performance against a placebo, market success and reimbursement often depend on proving non-inferiority or superiority to the existing pioneer drug.

6.2.1. Non-Inferiority Trial Design

Most follow-on agents are evaluated using non-inferiority trials, which aim to show that the new drug is not significantly worse than the established pioneer within a predefined margin. This ensures that even if the new agent does not offer a breakthrough in efficacy, it provides a viable alternative with a comparable safety profile [31].

6.2.2. The Role of Real-World Evidence

Post-marketing surveillance and real-world evidence (RWE) play a crucial role in validating the utility of follow-on drugs. Long-term observational studies often reveal subtle differences in safety or effectiveness that were not apparent in the controlled environment of a clinical trial. This ongoing evaluation helps clinicians identify specific patient subgroups that benefit more from a follow-on agent than the pioneer [32].

7. Conclusion

The classification of follow-on pharmaceuticals as mere imitations overlooks the sophisticated medicinal chemistry and clinical necessity that drive their development. Iterative innovation serves as a critical mechanism for refining the therapeutic index of established drug classes, transforming early prototypes into optimized treatments with superior pharmacokinetic profiles and reduced toxicity. The availability of multiple agents within a single class provides a necessary safeguard against the inherent variability of human biology, allowing clinicians to navigate genetic polymorphisms and varying patient tolerances that may render a pioneer drug ineffective or hazardous for specific individuals. Beyond clinical utility, follow-on drugs facilitate a competitive economic environment that incentivizes efficiency and broadens patient access through price moderation and supply chain diversification. While the tension between incremental advancement and breakthrough discovery remains a central theme in pharmaceutical policy, it is evident that follow-on agents are not a diversion of resources but a prerequisite for the maturation of any therapeutic category.

References

[1] DiMasi, J. A., & Faden, L. B. (2011). Competitiveness in follow-on drug R&D: a world-wide analysis of product launches. Nature Reviews Drug Discovery, 10(1), 23-27.

[2] Hollis, A. (2004). Me-too drugs: is there a problem? Health Economics, 13(2), 163-174.

[3] Aronson, J. K. (2006). "Me-too" pharmaceutical products and therapeutic excellence. British Journal of Clinical Pharmacology, 61(5), 499-501.

[4] Wertheimer, A. I., & Santella, T. M. (2004). Pharmacoevolution: The Advantages of Incremental Innovation. International Pharmaceutical Federation.

[5] Gagne, J. J., & Choudhry, N. K. (2011). Fast-follower drugs: a benchmark for evidence-based prescribing. Archives of Internal Medicine, 171(21), 1914-1920.

[6] Meanwell, N. A. (2011). Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design. Journal of Medicinal Chemistry, 54(8), 2529-2591.

[7] Andersson, T., et al. (2001). Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clinical Pharmacokinetics, 40(6), 411-426.

[8] Patani, G. A., & LaVoie, E. J. (1996). Bioisosterism: A rational approach in drug design. Chemical Reviews, 96(8), 3147-3176.

[9] Lesch, J. E. (2007). The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine. Oxford University Press.

[10] Sliwoski, G., et al. (2014). Computational methods in drug discovery. Pharmacological Reviews, 66(1), 334-395.

[11] Eichler, H. G., et al. (2010). Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nature Reviews Drug Discovery, 9(4), 277-286.

[12] Garattini, S., & Bertele, V. (2002). Efficacy, safety, and cost of 'me-too' drugs. BMJ, 325(7376), 1360-1361.

[13] Zhang, Y., & Benet, L. Z. (2001). The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clinical Pharmacokinetics, 40(3), 159-168.

[14] Meredith, P. A., & Elliott, H. L. (1992). Clinical pharmacokinetics of amlodipine. Clinical Pharmacokinetics, 22(1), 22-31.

[15] de Miranda, P., & Blum, M. R. (1983). Pharmacokinetics of acyclovir after intravenous and oral administration. Journal of Antimicrobial Chemotherapy, 12(suppl_B), 29-37.

[16] Kenakin, T. (2004). Principles: Receptor theory in pharmacology. Trends in Pharmacological Sciences, 25(4), 186-192.

[17] Cruickshank, J. M. (2007). Are beta-blockers as efficacious in patients with diabetes as in those without? Nature Clinical Practice Cardiovascular Medicine, 4(12), 642-643.

[18] Istvan, E. S., & Deisenhofer, J. (2001). Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 292(5519), 1160-1164.

[19] Evans, W. E., & Relling, M. V. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286(5439), 487-491.

[20] Preskorn, S. H. (1997). Comparison of the effects of SSRIs on CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Human Psychopharmacology, 12(S1), S33-S43.

[21] Robinson, M. (2004). Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. International Journal of Clinical Practice, 58(1), 51-61.

[22] Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353(5), 487-497.

[23] Lu, Z. J., & Comanor, W. S. (1998). Strategic pricing of new pharmaceuticals. Review of Economics and Statistics, 80(1), 108-118.

[24] Lichtenberg, F. R., & Philipson, T. J. (2002). The dual effects of intellectual property on pharmaceutical innovation. Health Affairs, 21(6), 129-136.

[25] Huskamp, H. A. (2003). Managing psychotropic drug costs: will formulations of the future be as effective? Health Affairs, 22(5), 84-96.

[26] Woodcock, J., & Wosinska, M. (2013). Economic and technological drivers of drug shortages. Clinical Pharmacology & Therapeutics, 93(2), 170-176.

[27] DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22(2), 151-185.

[28] Kneller, R. (2010). The importance of new companies for drug discovery: origins of a decade of new drugs. Nature Reviews Drug Discovery, 9(11), 867-882.

[29] Jones, P. H., et al. (2003). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). American Journal of Cardiology, 92(2), 152-160.

[30] Hemphill, C. S., & Sampat, B. N. (2012). Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics, 31(2), 327-339.

[31] Piaggio, G., et al. (2006). Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT statement. JAMA, 295(10), 1152-1160.

[32] Sherman, R. E., et al. (2016). Real-world evidence what is it and what can it tell us? New England Journal of Medicine, 375(23), 2293-2297.